Introduction
Telomeres are found at the end of linear chromosomes and consist of short repetitive sequences essential for the maintenance of normal chromosome structure and function (Wellinger and Sen, 1997) . With each cell division, telomeres shorten due to the inability of DNA polymerases to replicate the ends of linear DNA molecules. However, telomere erosion is counteracted by the activity of the enzyme telomerase, a ribonuclear protein with reverse transcriptase activity, which adds telomeric repeats to the chromosomal termini (Morin, 1997; Nakamura et al., 1997) . The genes for the human, (hTR), and mouse, (terc), RNA components have recently been cloned, as has the human protein component; (hTRT) (Blasco et al., 1995; Feng et al., 1995; Nakamura et al., 1997; Soder et al., 1997b,c) . Whilst telomerase expression is detectable in normal embryonic tissues and germline stem cells, telomerase expression is repressed in most normal postnatal somatic cells (Blasco et al., 1995; Feng et al., 1995; Prowse and Greider, 1995; Soder et al., 1997a; Wright et al., 1996) . The lack of telomerase expression may be the major reason for the progressive loss of telomeric sequences in somatic cells, which is considered to be one regulatory mechanism which monitors the number of times a cell divides before entering replicative senescence (Campisi, 1997) . However, although telomerase appears to be stringently repressed in normal somatic tissues, there is substantial evidence to suggest that telomerase is expressed in the majority of human cancers and contributing to the immortal phenotype through the maintenance of telomere integrity (Holt et al., 1997; Kim, 1997; Shay and Bacchetti, 1997) .
The regulation of telomerase expression is likely to be a complex issue including transcriptional activity of the telomerase RNA and protein component genes, interaction of telomerase with other telomere associated proteins and post-translational modi®cation of the enzyme complex. However, at present there are few studies which directly address the mechanisms regulating telomerase expression in normal and cancer cells (Bodnar et al., 1996; Broccoli et al., 1997; Li et al., 1997; Mandal and Kumar, 1997; Morin, 1997; Nakamura et al., 1997; Soder et al., 1997a) . To identify elements important for the regulation of telomerase RNA genes, we have cloned genomic DNA sequences encompassing both the human and mouse telomerase RNA genes, including 5'-¯anking regions.
Results
Cloning of genomic sequences encompassing the human and mouse telomerase RNA genes
We have previously reported the identi®cation of P1 genomic clones for the human, (hTR), and mouse, (terc), telomerase RNA genes (Soder et al., 1997b,c) . In order to obtain sequences¯anking the genes, the P1 genomic clones were digested with EcoRI and HindIII, subcloned into the plasmid vector, pBluescript, and colonies containing hTR or terc sequences identi®ed by hybridization to PCR generated probes speci®c for the genes. A 1.3 kb genomic clone encompassing hTR was isolated as was a 4 kb genomic clone emcompassing terc (Figure 1) .
A BLAST search using the 1.3 kb human sequence identi®ed three high-scoring segment pairs: HSU85256, HSU86046 and MMU33831. HSU85256 (598 bp of sequence) and HSU86046, (545 bp of sequence), are published sequences for the transcribed region of the human telomerase RNA gene and con®rmed that we had cloned genomic sequences encompassing hTR (Bryan et al., 1997; Feng et al., 1995) . MMU33831 is the sequence of the transcribed region of the mouse telomerase RNA gene which has previously been shown to have homology to the human gene (Blasco et al., 1995) . In addition to the BLAST search, a text search for telomerase sequences carried out on the NCBI database revealed a 2.4 kb sequence, (I31750), from US patent number 5583016, (Inventors: Villeponteau B, Feng J, Funk W and Andrews WH, assigned to the Geron Corporation), which aligned with the HindIII site at the 3'-end of our genomic clone and extended 5' to the EcoRI site in our clone and thus completely overlapped the sequence of our 1.3 kb clone with only minor base dierences. We extended the sequence of our P1 clone 5' to the EcoRI site by designing a PCR primer, hProm867 from the patent sequence and cloning and sequencing the PCR product using the P1 clone as a template. In total we have generated 1765 bp of sequence information encompassing the human telomerase RNA gene and a schematic representation of this is shown in Figure 1 . Thus we have extended the sequence in both the 3' and 5' anking regions of hTR and con®rmed the unpublished patent sequence.
A BLAST search using the 4 kb mouse sequence identi®ed both the published human gene sequences, (HSU85256, HSU86046) and the published sequence for the transcribed region of the mouse gene, MMU33831, (590 bp of sequence) (Blasco et al., 1995; Bryan et al., 1997; Feng et al., 1995) . In order to con®rm that the genomic sequence obtained from the P1 subclone was genuine, we cloned 5'-¯anking sequences using genomic DNA from Balb/c mice in PCR reactions. Sequence analysis of the Balb/c clones were identical to the P1 sequence except for minor polymorphisms (data not shown). Thus we have extended the published sequence for the coding region of the mouse telomerase RNA gene in both the 3' and 5'¯anking regions of terc. A schematic representation of the 4 kb of sequence information encompassing the mouse telomerase RNA gene is shown in Figure 1 .
Analysis of nucleotide sequence encompassing the human and mouse telomerase RNA genes To investigate the relationship between the human and mouse genomic clones, sequence comparisons were carried out. The transcribed regions of the two genes showed 67% identity in keeping with the published estimate (Feng et al., 1995) . However, no signi®cant sequence identity could be identi®ed in either the 5'-or 3'-regions¯anking the transcribed sequences.
Both the human and mouse sequences were analysed for CpG islands by GRAIL. CpG islands were de®ned as regions larger than 200 bp, with an average GC content greater than 50% and the ratio of observed versus expected CpGs greter than 0.6 (Gardiner- Garden and Frommer, 1987) . Interestingly, both the human and mouse genes lie within CpG islands, (see Figure 1 ). The human gene is covered by a CpG island 733 bp in length, with a GC content of 66% and a ratio of observed versus expected CpGs of 0.89. The mouse gene is covered by a CpG island of 659 bp in length, with a GC content of 64% and a ratio of observed versus expected CpGs of 0.81.
The 5'-¯anking regions of the human and mouse telomerase RNA genes were also analysed for potential transcription factor recognition sites. As shown in Figure 2 , a number of potential binding sites can be identi®ed, including consensus sequences for glucocorticoid/progesterone/androgen receptor binding, AP1 and Ets family members. CCAAT box's are found in both genes close to the published transcriptional start sites (Blasco et al., 1995; Feng et al., 1995) , however, there is no obvious TATA box in the mouse gene with the human gene TATA box consensus sequence being in the reverse orientation. The mouse promoter region also contains a run of CpA dinucleotide repeats which may be of use in developing microsatellite genetic markers for this gene.
Transfection assays detect promoter activity in the 5'-¯anking regions of the human and mouse telomerase RNA genes To identify whether the 5'-¯anking DNA of the telomerase RNA genes exhibited promoter activity, sequences were fused to a ®re¯y luciferase reporter gene, (pGL3-Basic). The transcriptional start sites for both the human and mouse telomerase RNA genes Figure 1 Restriction enzyme map of the genomic clones encompassing the human and mouse telomerase RNA genes. The transcribed regions of hTR and terc are depicted as black boxes within the central regions of the genomic sequences and the site of the template sequence within the telomerase RNA genes is indicated. The position of the CpG islands are shown as a box beneath the genomic sequence. Numbers in brackets refer to the nucleotide position within the sequence. The 3'-end of all the human promoter fragments is shown as hProm and fragments extend 5-prime to hProm867, hProm697, hProm341 and hProm111. The 3'-end of all the mouse promoter fragments is shown as mProm and fragments extend 5-prime to mProm628, mProm458, mProm418, mProm267, mProm208, mProm136. The numbers after the pre®x hProm or mProm refer to the number of nucleotides of genomic sequence contained in the promoter fragment have been established (Blasco et al., 1995; Feng et al., 1995) . Various promoter constructs containing the transcriptional start site were therefore generated (see Figures 2 and 3) .
Human promoter constructs containing truncated portions of the 5'-¯anking region were transiently transfected into HeLa and GM847 cells (Figure 3a) . HeLa is a telomerase positive cervical carcinoma cell line, GM847 is a SV40-immortalized skin ®broblast cell line which expresses the telomerase RNA component but is telomerase-negative (Bryan et al., 1997) . As shown in Figure 3a , promoter activity was observed in both cell lines with fragments containing 341 bp or more (from position 7272, see Figures 2a and 3a) . The highest luciferase activity was observed with construct hProm505 which contains a 505 bp fragment, (position 7463, see Figure 2 ). Construct, hProm111, which contains only 111 bp of 5'-¯anking sequence (position 742, see Figures 2a and 3a ), produced a dramatically reduced level of luciferase activity (Figure 3a) , and is not sucient on its own for promoter activity. Thus, a minimal promoter sequence can be de®ned as extending 272 bp upstream of the transcription start site, and that elements responsible for promoter activity must be contained in a 231 bp region between 7272 bp and 742 bp, (Figures 2a and 3a) .
Mouse promoter constructs containing various truncated portions of the 5'-¯anking region were transiently transfected into Swiss3T3 and A9 cells (Figure 3b ). Swiss3T3 cells are an embryo derived line and A9 cells are of areolar and adipose origin. Both cell lines are telomerase positive. As shown in Figure  3b , promoter activity was observed in both cell lines with fragments containing 208 bp or more (from position 794, see Figure 2b ). Construct mProm136, which contains only 136 bp of 5'-¯anking sequence (position 722, see Figure 2b ), produced dramatically reduced levels of luciferase activity (Figure 2b ). Thus, a minimal promoter sequence can be de®ned as extending 94 bp upstream of the transcription start site, and that elements responsible for promoter activity must be contained in a 73 bp region between 794 bp and 722 bp (Figures 2b and 3b) .
Transfection of the human promoter construct hProm867 into mouse cells gave very strong promoter activity, with up to twice that of the strongest mouse construct, and transfection of the mouse promoter construct, mProm628 into human cells also showed luciferase activity at around 25% of the strongest human construct (data not shown).
Discussion
The levels of telomerase RNA gene expression vary during normal development and between normal and cancerous cells and tissues (Avilion et al., 1996; Bestilny et al., 1996; Blasco et al., 1995 Blasco et al., , 1996 Bodnar et al., 1996; Broccoli et al., 1996; Feng et al., 1995; Kuniyasu et al., 1997; Soder et al., 1997a) . Knowledge of telomerase RNA gene expression should therefore aid our understanding of the signal transduction pathways linking telomere attrition to proliferation, cellular senescence, dierentiation and oncogenesis. As a ®rst step towards this goal, we have cloned the promoter regions of the human (hTR) and mouse (terc), telomerase RNA genes In general, there are no signi®cant sequence homologies between the promoter regions of the human and mouse telomerase RNA genes. Indeed, there is considerable debate as to whether telomere length is regulated in a similar fashion in humans and mouse (Blasco et al., 1997; Kipling, 1997a,b; Zakian, 1997) . However, mouse models represent a valuable resource with which to study the role of telomerase in cellular senescence and tumour progression and mouse models are likely to be required to investigate new therapies based on telomerase inhibition. In addition, the developmental regulation of telomerase will be more easily approached in mice (Bestilny et al., 1996; Blasco et al., 1995 Blasco et al., , 1996 Blasco et al., , 1997 Broccoli et al., 1996; Prowse and Greider, 1995) . Thus, any dierences between the two species may in fact aid our understanding of the function for telomerase in maintaining genome stability and may be important in developing good murine models for human disease or developmental processes. Whether the sequence divergence between the human and mouse gene promoters has any functional consequences can now be studied.
Despite the lack of sequence similarity between the human and mouse telomerase RNA gene promoter regions, they both have consensus sites for the binding of transcription factors implicated in haematopoiesis and leukaemogenesis such as GATA-1, PU.1, PEA2/ PEBP2, C/EBP and c-Ets-2 (Tenen et al., 1997) . These data will therefore be of interest in examining the basis for the detection of telomerase activity in normal and malignant haematopoietic cells (Bodnar et al., 1996; Cheng et al., 1997; Holt et al., 1997; Norrback and Roos, 1997; Pan et al., 1997) . The human and mouse telomerase RNA genes do share an interesting similarity, in that they both lie in CpG islands, and thus their expression may be regulated by methylation. DNA methylation is thought to be important for gene regulation during normal development and cellular senescence, and abnormal methylation patterns may be a fundamental change in tumour progression (Baylin et al., 1991; Bird, 1996; Laird and Jaenisch, 1996; Vertino et al., 1994; Wilson and Jones, 1983) . Thus it has been suggested that aberrant CpG island methylation during normal ageing process, could contribute to immortalization by interfering with expression of`mortality' genes, of which hTR and terc can be included (Vertino et al., 1994; Wilson and Jones, 1983) . We are currently testing the relationship between DNA methylation and telomerase RNA gene expression.
Turning to the functional analysis of the cloned sequences, the minimal promoter for hTR resides within a region of 272 bp upstream of the published transcriptional start site (Feng et al., 1995) (Figures 2a  and 3a ). There are a number of potential transcription factor binding sites in this region including consensus sequences for AP1, Sp1, PEA2/PEBP2, PEA3 and PU.1. Interestingly, the expression in the fos/jun family of proteins, which determine AP1 activity, are suppressed during the onset of senescence and would be predicted to lead to a reduction in AP1 activity in senescent cells (Campisi, 1997; Irving et al., 1992; Riabowol et al., 1992; Seshadri and Campisi, 1990) . AP1 also responds to protein kinase C, and it has recently been demonstrated that hTR expression is induced by protein kinase C during T-cell activation (Bodnar et al., 1996) . Extending the promoter region to 463 bp upstream of the transciptional start site, increases the luciferase activity to its maximum level (Figures 2a and 3a) . This region contains several consensus binding sites for glucocorticoid/progesterone/androgen receptor binding, which may contribute to the maximal activity demonstrted by hProm505. A reduction in promoter activity is observed on extending the promoter fragments to include more 5'-sequence (Figure 3a) , suggesting that sequences towards the 5'-end of the clone may in¯uence promoter activity in a negative fashion.
The minimal promoter for terc resides in a 94 bp region upstream of the published transcriptional start site (Blasco et al., 1995) , (Figures 2b and 3b) . A striking feature of this region is the presence of three AP-2 consensus sites, two of which are coupled to c-Ets-2 sites and all these elements are contained in the 73 bp region required for promoter activity (Figures 2b  and 3b ). Oncogenic Ras gene signalling has been shown to operate through c-Ets-2 binding sites, thus there is a testable relationship between oncogene activation during tumour progression and telomerase RNA gene transcriptional activity (Galang et al., 1994; Wasylyk et al., 1994) . A reduction in promoter activity is observed on extending the promoter fragments to Figure 3b, mProm628) , suggesting that sequences towards the 5'-end of the clone may in¯uence promoter activity in a negative fashion.
These studies have a number of implications for the development of new transcription based therapies for cancer (Cai et al., 1996; Connors, 1995; Miller and Whelan, 1997; Peterson and Baichwal, 1993) . Directly down-regulating expression of the telomerase RNA gene through manipulation of transcription factors should be an eective anticancer therapy and the cloning of the hTR gene promoter will allow the analysis of therapeutic molecules which modulate hTR promoter activity (Cai et al., 1996; Peterson and Baichwal, 1993; Sharma et al., 1997) . Indeed, by using a human cell line which has telomerase activity (HeLa) and one which expresses the hTR gene but is telomerase negative (GM847) (Bryan et al., 1997) , we have established a system in which the speci®city of transcriptional manipulation of hTR can be examined. In comparison to HeLa, the growth of GM847 does not appear to be dependant on telomerase expression, thus transcriptional targeting of hTR in GM847 should have no cellular eects, whereas HeLa should be sensitive to the predicted anti-proliferative eects of the transcriptional targeting. In addition, we have recently shown tumourspeci®c patterns of hTR gene expression with clear dierentials in expression between cancerous and adjacent normal tissue (Soder et al., 1997a,b) . Therefore, the hTR gene promoter may be of considerable use in genetic therapies requiring selective expression of therapeutic genes in cancer cells expressing high levels of hTR (Connors, 1995; Miller and Whelan, 1997; Soder et al., 1997a) . The constructs described in the present study will be ideal for more focused gene therapy studies and the development of transcription based therapeutics.
In conclusion, by de®ning the human and mouse telomerase RNA gene promoters we are now in a position to identify the factors which repress or activate hTR and terc expression during normal development and senescence and determine whether these pathways dier in the regulation of telomerase RNA gene expression in cancer progression. We can now begin to address the question of whether signals arising from critically short telomeres directly lead to telomerase activation and whether telomerase RNA gene expression is directly linked to the oncogenic process. These studies are critical to our understanding of how telomerase activity is repressed or activated and to the identi®cation of the cell signalling pathways which are utilized to co-ordinately regulate the expression of the genes encoding the telomerase enzyme complex.
Materials and methods
Cloning of sequences encompassing the human and mouse telomerase RNA genes
We have previously reported the identi®cation of genomic clones in P1 vectors containing hTR and terc transcribed sequences (Soder et al., 1997b, c) . The human P1 clone, 9913, is derived from a human foreskin ®broblast P1 library and the mouse P1 clone, 11792, is derived from a mouse C127 ®broblast P1 library. Brie¯y, in order to subclone the promoter regions, the P1 clones were digested with EcoRI and HindIII and ligated into pBluescript. Colonies containing telomerase RNA gene sequences were identi®ed by hybridization with PCR generated probes as previously described (Soder et al., 1997b,c) . Plasmid DNA was prepared from positively hybridizing colonies, and inserts sequenced on both strands by dideoxy chain termination using the ABI PRISM dye teminator cycle sequencing kit (PE Applied Biosystems, Warrington, UK) and 25 ng oligonucleotide primers. Dye labelled products were resolved and detected using the Applied Biosystems DNA sequencer ABI373. Sequence was analysed using the Sequencing Analysis program v3.0. Homology searches carried out using BLAST (Basic Local Alignment Search Tool), National Centre for Biotechnology Information (NCBI): http://www.ncbi.nlm.nih.gov/. Sequence was analysed for potential transcription factor binding sites by TESS: Transcription Element Search Software on the WWW, Jonathan Schug and G Christian Overton, Technical Report CBIL-TR-1997-1001-v0.0, of the Computational Biology and Informatics Laboratory, School of Medicine, University of Pennsylvania, 1997, http:// agave.humgen.upenn.edu/tess/index.html. Identi®cation of CpG islands was carried out using GRAIL: Gene Recognition and Assembly Internet Link, http://compbio.ornl.gov/ Grail-1.3/. The full sequences have been submitted to GenBank, accession numbers AF047386, AF047387.
